Bionomics Results Presentation Deck

Bionomics: Clinical Stage Company with Focused CNS Pipeline and Multiple Catalysts on the Horizon Clinical stage ion channel focused company targeting Social Anxiety Disorder (SAD), Post-Traumatic Stress Disorder (PTSD) and cognitive dysfunction associated with Alzheimer's disease, schizophrenia and other CNS conditions through proprietary programs, partnerships and collaborations* Program Proprietary Programs: BNC210 a7 receptor NAM EmpathBio BNC210 3 Collaboration Programs: MERCK Collaboration a7 receptor PAM Indication Social Anxiety Disorder (SAD) Post-Traumatic Stress Disorder (PTSD) +MDMA derivative EMP-01 (PTSD) 2 candidates for Cognitive Deficit in Alzheimer's Pre-Clinical Phase 1 PREVAIL Phase 2 ATTUNE Phase 3 *Pipeline of partnering candidates targeting potassium (Kv) and sodium (Nav) ion channels and partnership on legacy oncology program with Carina Biotech. Fast Track Study completed Fast Track MOU to explore combination treatment regimen Status Topline Data Annc. YE 2022 Study underway Topline Data: mid 2023 Feasibility assessment Phase 1 safety & biomarker studies ongoing Bionomics NAM = Negative Allosteric Modulator PAM = Positive Allosteric Modulator

View entire presentation